Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $1.20 · Revenue $401.41M · 4 analysts
Est. EPS $1.48 · Revenue $426.92M · 4 analysts
Est. EPS $4.71 · Revenue $1.59B · 5 analysts
Est. EPS $1.38 · Revenue $424.26M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.4B | +17.5% | +4.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $177.7M | +1168.1% | +6.8% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +67.1% | +6.2% | +0.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +13.5% | +86.8% | +3.1% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +12.7% | +979.2% | +2.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $174.9M | +18.8% | -55.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +12.5% | +1.1% | -57.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 15.4% | -20.7% | -5.3% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.64x | +10.6% | -4.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.8B | +19.1% | +4.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 4.52 vs 3.79 | +19.4% | 0.88 vs 1.20 | -26.9% |
| Revenue Surprise | $1.4B vs $1.4B | +1.7% | $390.0M vs $401.4M | -2.8% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Narayan Shruthi | officer: President | Common Stock | A | 3,060 | — |
| May 19, 2026 | Elsesser Adam | director, officer: CEO | Common Stock | D | 77,000 | — |
| Apr 2, 2026 | Grewal Harpreet | director | Common Stock | D | 100 | $328.22 |
| Mar 15, 2026 | Narayan Shruthi | officer: President | Common Stock | D | 117 | $336.18 |
| Mar 15, 2026 | Roberts Johanna | officer: EVP, Gen. Counsel & Secretary | Common Stock | D | 186 | $336.18 |
Operator: Ladies and gentlemen, good afternoon. My name is Abby, and I'll be your conference operator today. At this time, I would like to welcome everyone to Penumbra's Third Quarter 2025 Conference Call. [Operator Instructions] Thank you. And I would now like to introduce Ms. Cecilia Furlong, Business Development and Investor Relations for Penumbra. Ms. Furlong, you may begin your conference. Cecilia Furlong: Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for the third quarter of 2025. A copy of the press release and financial tables, which includes a GAAP to non-GAAP reconciliation, can be viewed under the Investors tab on our company website at www.penumbrainc.com. With me on today's call are Adam Elsesser, Chairman and CEO; Shruthi Narayan, President; and Maggie Yuen, Chief Financial Officer. Also joining us for the Q&A portion of the call is Jason Mills, EVP, Strategy. During the course of this conference call, the company will make forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial performance, commercialization, clinical trials, regulatory status, quality, compliance and business trends. Actual results could differ materially from those stated or implied by our forward-looking statements due to certain risks and uncertainties, including those referenced in our 10-K for the year ended December 31, 2024, filed with the SEC. As a result, we caution you against placing undue reliance on these forward-looking statements, and we encourage you to review our periodic filings with the SEC, including the 10-K previously mentioned, for a more complete discussion of these factors and other risks that may affect our future results or the market price of our stock. Penumbra disclaims any duty to update or revise our forward-looking statements as a result of new information, future events, developments or otherwise. On this call, financial results for revenue and gross margin are presented on a GAAP basis, while operating expenses, operating income, and adjusted EBITDA are presented on a non-GAAP basis. The corresponding GAAP measures and a reconciliation of GAAP to non-GAAP financial measures are provided in our posted press release. Non-GAAP operating expenses and operating income exclude expenses related to the wind down of our Immersive Healthcare business in the third quarter of 2024 of $5 million and adjusted EBITDA excludes wind-down expenses, stock compensation expense, depreciation and amortization, provision for income taxes and interest income expenses. And with that, I would like to turn the call over to Adam. Adam Elsesser: Thank you, Cecilia. Good afternoon. Thank you for joining Penumbra's Third Quarter 2025 Conference Call. In the third quarter, we generated total revenue of $354.7 million, representing underlying year-over-year growth of 17.8% on a reported …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Adam Elsesser | Co-Founder, Chairman & Chief Executive Officer | USD 851,620 | Male | 1962 | Active |
Shruthi Narayan | President | USD 737,351 | Female | 1985 | Active |
Maggie S. Yuen | Chief Financial Officer | USD 722,467 | Female | 1972 | Active |
Johanna Roberts | Executive Vice President, General Counsel & Secretary | USD 722,371 | Female | 1972 | Active |
Lambert Shiu | Chief Accounting Officer | USD 601,141 | Male | 1980 | Active |
Arani Bose | Co-Founder & Director | USD 60,000 | — | 1962 | Active |
Pankaj Tiwari | Executive Vice President & Chief Information Officer | — | Male | — | Active |
Ben Sorci | Executive Vice President of Operations | — | Male | — | Active |
Ben Tompkins | Executive Vice President of Development & Compliance | — | Male | — | Active |
Jee Hamlyn-Harris | Investor Relations Officer | — | Female | — | Active |
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Bank of Nova Scotia boosted its stake in Penumbra, Inc. (NYSE: PEN) by 14,837.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,820 shares of the company's stock after purchasing an additional 210,402 shares during the quarter. Bank
California Public Employees Retirement System lifted its stake in shares of Penumbra, Inc. (NYSE: PEN) by 25.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,421 shares of the company's stock after purchasing an additional 12,108 shares during
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire ALAMEDA, Cal
First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO).
